Trial Profile

A Phase 2 Study to Assess the Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gusacitinib (Primary) ; Vismodegib (Primary)
Indications Basal cell cancer
Focus Therapeutic Use
Sponsors Stamford Pharmaceuticals

Most Recent Events

11 Apr 2024 According to a Stamford Pharmaceuticals media release, the phase 2 clinical study is funded with proceeds from a Series A led by Tenmile Ventures, Prevail Partners and other syndicate parties completed in October 2023.
11 Apr 2024 According to a Stamford Pharmaceuticals media release, the company announced the initiation of its locally advanced basal cell carcinoma (laBCC) trial
11 Apr 2024 Status changed from not yet recruiting to recruiting, according to a Stamford Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com